Biosimilar Hormones Market Anticipated To Witness Robust Growth, Surpassing $11.77 Billion By 2029

The Biosimilar Hormones Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]._x000D_
_x000D_
What Is the Current Biosimilar Hormones Market Size and Its Estimated Growth Rate?_x000D_
The biosimilar hormones market has grown substantially in recent years. It will grow from $3.9 billion in 2024 to $4.98 billion in 2025 at a compound annual growth rate (CAGR) of 27.5%. Factors contributing to this growth include the growing prevalence of chronic diseases, an aging population, increased awareness of biosimilar hormones, and improved access to healthcare._x000D_
_x000D_
The biosimilar hormones market is expected to see exponential growth, reaching $11.77 billion in 2029 at a CAGR of 24.0%. Growth factors include increasing patient acceptance, enhanced manufacturing, rising clinical data, healthcare access expansion, and more hormone targets. Prominent trends include personalized hormone therapies, patient-focused care, new product introductions, and affordability strategies._x000D_
_x000D_
Purchase the full report for exclusive industry analysis:_x000D_
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3432_x000D_
_x000D_
How Are Emerging Segments Shaping the Biosimilar Hormones Market Landscape?_x000D_
The biosimilar hormones market covered in this report is segmented -_x000D_
_x000D_
1) By Type: Teriparatide Biosimilars, Follitropin Alfa Biosimilars, Insulin Biosimilars, Somatropin Biosimilars, Other Types_x000D_
2) By Application: Research & Biotechnology, Diagnostics, Biocatalysts, Therapeutics, Other Applications_x000D_
3) By Distribution Channel: Hospital And Retail Pharmacy, Online Pharmacy/pharmacy, Specialty Clinics_x000D_
_x000D_
Subsegments:_x000D_
1) By Teriparatide Biosimilars: Osteoporosis Treatment, Bone Health Maintenance_x000D_
2) By Follitropin Alfa Biosimilars: Infertility Treatment, Assisted Reproductive Technology (ART)_x000D_
3) By Insulin Biosimilars: Type 1 Diabetes Management, Type 2 Diabetes Management_x000D_
4) By Somatropin Biosimilars: Growth Hormone Deficiency Treatment, Pediatric Growth Disorders_x000D_
5) By Other Types: Thyroid Hormones, Corticosteroids_x000D_
_x000D_
Get your free sample here:_x000D_
https://www.thebusinessresearchcompany.com/sample.aspx?id=3432&type=smp_x000D_
_x000D_
Which Growth Factors Are Influencing Biosimilar Hormones Market Expansion?_x000D_
A growing number of hormone-related deficiencies, including metabolic and growth hormones, is contributing to the growth of the biosimilar hormones market. Treatments have evolved with higher demand due to these conditions. As noted by the British Medical Journal in January 2022, global prevalence of growth hormone deficiency in children ranges from 1 in 3,500 to 1 in 10,000, with 6,000 U.S. adults expected to be diagnosed annually, according to a June 2022 Medscape report._x000D_
_x000D_
Who Are the Dominant Players Across Different Biosimilar Hormones Market Segments?_x000D_
Major companies operating in the biosimilar hormones market include Teva Pharmaceutical Industries Ltd., Gedeon Richter Plc., Intas Pharmaceuticals Ltd., Biocon Limited, Mylan, Sanofi, Sandoz Group AG, LG Life Sciences, Ferring Pharmaceuticals, GC Pharma, Pfizer Inc., Dr. Reddy's Laboratories, Amgen Inc., Eli Lilly and Company, Celltrion Inc., Samsungbioepis Co.Ltd, Merck & Co., Biogen Inc., Boehringer Ingelheim, Alvotech, BioXpress Therapeutics, Cipla Limited, Lupin Ltd., Stada Arzneimittel AG, Torrent Pharmaceuticals, Zydus Cadila, Accord Healthcare, Hetero Drugs, Wockhardt_x000D_
_x000D_
What Biosimilar Hormones Market Trends Are Gaining Traction Across Different Segments?_x000D_
Key players in the biosimilar hormones market are launching new products in underserved regions to increase accessibility and maximize market share. These companies are targeting various locations to enhance sales and profits. For example, in February 2022, Alvotech Holdings S.A. partnered with Fuji Pharma Co. Ltd. to develop biosimilar drugs in Japan, aiming to expand their strategic alliance to create and promote biosimilar medicines in the region._x000D_
_x000D_
Get the full report for exclusive industry analysis:_x000D_
https://www.thebusinessresearchcompany.com/report/biosimilar-hormone-global-market-report_x000D_
_x000D_
Which Geographic Regions Are Expected to Dominate the Biosimilar Hormones Market in the Coming Years?_x000D_
The countries covered in the biosimilar hormones market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada._x000D_
_x000D_
Frequently Asked Questions:_x000D_
1. What Is the Market Size and Growth Rate of the Biosimilar Hormones Market?_x000D_
2. What is the CAGR expected in the Biosimilar Hormones Market?_x000D_
3. What Are the Key Innovations Transforming the Biosimilar Hormones Industry?_x000D_
4. Which Region Is Leading the Biosimilar Hormones Market?

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.